Official ESCRS | European Society of Cataract & Refractive Surgeons
Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Surgical management and use of 5-Fluorouracil in pyogenic granuloma after primary pterygium surgery

Poster Details

First Author: A. Gkounta GREECE

Co Author(s):    S. Souki   E. Mavrikakis   I. Papaefthymiou   T. Papadaki           

Abstract Details

Purpose:

Purpose: To present the treatment of pyogenic granuloma growing after pterygium surgery.

Setting:

1 Department of Ophthalmology, G. Gennimatas Hospital, Athens, Greece.  2 First Department of Ophthalmology, National and Kapodistrian University of Athens, Athens, Greece.

Methods:

A 34 year-old Caucasian man underwent surgical excision of an inflammatory pterygium OD.The fibrovascular proliferation was excised from cornea with blade and was subsequently bluntly dissected from the overlying conjunctiva and underlying sclera. Conjunctival margins were approximated with absorbable interrupted 8-0 sutures at 2mm distance from limbus. Postoperatively, topical antibiotic and steroid was prescribed. At 2months follow-up, the patient presented with conjunctival injection and tearing. Slit lamp examination revealed proliferative tissue on the surgical wound. Excision and a subconjunctival injection of 6IU 5-Fluorouracil(5-FU) was performed, followed by 2 more injections of 6UI 5-FU (at weeks 2 and 3, postoperatively).

Results:

Histological evaluation of the conjunctival specimen revealed inflammatory granuloma tissue, with squared epithelium covered with fibropyogenic exudate. No major complications were related to the use of 5-FU during the 6-month follow up.

Conclusions:

This case report suggests that 5-FU is safe and effective for the management of a postoperative pyogenic granuloma.

Financial Disclosure:

NONE

Back to Poster listing